Scientists reprogram immune cells to attack common cancer mutation

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along with a vaccine to boost the immune response. Up to 210 adults with cancers like colorectal, lung, or breast cancer that have not responded to standard therapy will participate. The main goals are to see if the treatment shrinks tumors and to check for side effects.